Comparative efficacy of dioctahedral smectite (Smecta) and a probiotic preparation in chronic functional diarrhoea

The present study was designed to investigate the clinical efficacy and safety of dioctahedral smectite in Chinese patients with chronic functional diarrhoea and to compare this activity to a probiotic preparation.

Patients diagnosed with chronic functional diarrhoea (Rome II criteria), exclusion of blood, ova/parasites in the stool and a normal colonoscopy were included. After a 1-week period of baseline without any medication, they were prescribed three sachets of dioctahedral smectite 3 g, administered 1 h after the meals (Group A), or two capsules of Bifico 210 mg (Group B) for 28 consecutive days. Efficacy of the treatments was assessed on frequency of bowel movements and consistency of stool, as compared to baseline.

Four hundred and ten patients were included (258 males, 152 females; mean age 43.8 ± 13.9 years): 208 in Group A and 202 in Group B. In Group A, the mean number of stool per day decreased from 3.5 ± 1.0 at baseline to 2.0 ± 0.9 and from 3.3 ± 1.0 to 2.2 ± 0.9 in Group B (z = 2.699; P = 0.007). Decrease in stool number was significant with both treatments but more important with smectite at week 2 and remained significant throughout the treatment period. Stool consistency, assessed by the Bristol scale, also improved significantly over the treatment period, as compared to baseline (z = 3.310, P = 0.001).

Dioctahedral smectite appeared in this study to be an effective and safe treatment of chronic functional diarrhoea, its effect starting during the first week of treatment and consisting in a decrease in the frequency of daily bowel movements and improvement of stool consistency. Moreover, dioctahedral smectite displays a prolonged action after disruption of the treatment that may interfere with the natural course of the disease.     

Control study of oral rehydration solution (ORS)/ORS + dioctahedral smectite in hospitalized Thai infants with acute secretory diarrhea.

Dioctahedral smectite, a non systemic antidiarrheal agent, is mucoprotective and absorbs enterotoxins and rotavirus as demonstrated in animal models. Smectite has been successfully used in various countries in children and adults with acute diarrhea. This study was to assess the efficiency of smectite associated with rehydration in infants with acute secretory diarrhea. Sixty-two hospitalized Thai infants, aged 1-24 months, with acute secretory diarrhea were randomly divided into 2 groups receiving (1) oral rehydration solution (ORS) (30 cases), (2) ORS and Smectite (3.6 g/day) (32 cases). Both groups were comparable for age, weight, nutritional status and duration of symptoms before treatment. All 62 infants received lactose free formula and chicken rice soup as the standard diet. Stool frequency, weight change and duration of diarrhea were recorded. The mean duration of diarrhea was 84.7 +/- 48.5 hours in group 1, and 43.3 +/- 25.1 hours in group 2 (p = 0.005). The number of infants with diarrhea was significantly lower in group 2 on Day 1 (p < 0.01) and Day 3 (p = 0.001); furthermore 27% of infants in group 1 and 3% in group 2 had still diarrhea on Day 5. The stool frequency and weight changes were not statistically different in the two groups. No major side effects were observed except two cases of vomiting and hardened stools. It is concluded that (1) Smectite shortens the course of acute secretory diarrhea in Thai infants; (2) smectite may reduce the occurrence of prolonged diarrhea; furthermore (3) in our study dioctahedral smectite was found to be safe in children aged 1 to 24 months.     

Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome

BACKGROUND AND AIM: Dioctahedral smectite (DS) is natural adsorbent clay useful in treating acute diarrhea. The aim of this study was to determine DS efficacy on patients with diarrhea-predominant irritable bowel syndrome (D-IBS in a phase III-, 8-week-randomized, double-blind, placebo-controlled trial. METHODS: The 104 patients who met the D-IBS Rome II criteria were randomized to receive either DS (n = 52) or placebo (n = 52) treatment for 8 weeks (three sachets daily). The primary efficacy endpoint was the changes of the visual analog scale (VAS) score of IBS overall disorder and pain/discomfort-related symptoms after treatment on days 28 and 56, respectively. Other outcome measures included improvement of bowel movement disorders. The therapeutic global response was assessed by the patients and investigators at each visit, as was drug safety. RESULTS: Both treatments diminished overall disorder at each visit (P < 0.01), with respect to primary efficacy. This effect was further observed in DS-treated patients on day 56 (P = 0.0167). Placebo had no effect on the VAS score of pain/discomfort at any visit, whereas DS improved this score on days 28 and 56, respectively (P < 0.05). DS and placebo similarly diminished bowel disorders at each visit; however, only DS improved abdominal bloating (P < 0.01). The global therapeutic responses evaluated by the patients and investigators were similarly distributed. The study drug was well tolerated during the 8-week period. CONCLUSION: DS seems acceptable to treat D-IBS patients, particularly for pain-related symptoms.     

Preserved exocrine function in patients with acute cholera and acute non-cholera diarrhoea

Exocrine pancreatic function was assessed by means of the Lundh test in 14 patients with acute cholera and 18 patients with acute infectious non-cholera diarrhoea within the first 24 h of their admission. Mean tryptic activity amounted to 39.8 +/- 4.8 microEq/min/ml in the cholera group and to 64.4 +/- 11.0 microEq/min/ml in the non-cholera group. None of these patients shared a value below the lower limit of normal. In fact, the mean tryptic activity per 2 h was significantly higher than that reported previously in a control group from the Bengal area. It is therefore concluded that the exocrine pancreatic function is preserved and responds to food stimulation in various types of acute infectious diarrhoea, including cholera. These findings provide the pathophysiological background for the recent observation that oral rehydration solutions containing high-molecular-weight nutrients such as rice powder are at least as efficient or even more potent than the WHO-recommended glucose-electrolyte formula in acute diarrhoea.     

Preserved exocrine function in patients with acute cholera and acute non-cholera diarrhoea

Summary Exocrine pancreatic function was assessed by means of the Lundh test in 14 patients with acute cholera and 18 patients with acute infectious non-cholera diarrhoea within the first 24 h of their admission. Mean tryptic activity amounted to 39.8 ±4.8 μEq/min/ml in the cholera group and to 64.4±11.0 μEq/min/ml in the non-cholera group. None of these patients shared a value below the lower limit of normal. In fact, the mean tryptic activity per 2 h was significantly higher than that reported previously in a control group from the Bengal area. It is therefore concluded that the exocrine pancreatic function is preserved and responds to food stimulation in various types of acute infectious diarrhoea, including cholera. These findings provide the pathophysiological background for the recent observation that oral rehydration solutions containing high-molecular-weight nutrients such as rice powder are at least as efficient or even more potent than the WHO-recommended glucose-electrolyte formula in acute diarrhoea.     

Management of diarrhoea in HIV-infected patients

Human immunodeficiency virus (HIV) infection can weaken the immune system causing its inability to combat opportunistic infections. Managing the complexity of these opportunistic infections has created a challenge for healthcare professionals. Our knowledge on the aetiological agents causing opportunistic infections in immunocompromised hosts has increased over the last decade. Diarrhoeal diseases are frequent complications associated with HIV-infected patients. For most of the causes of diarrhoea, the clinical signs are non-specific, and the laboratory diagnostic workup is neither easy nor fast. This review provides data on aetiological approaches of common diarrhoeal diseases including viral, microbacterial, parasitic, bacterial and fungal infections, and HIV enteropathy; diagnostic evaluation; and treatment of diarrhoea in HIV-infected patients. This article will be helpful for those who are in the practice of managing diarrhoea in such patients.     

Etiology of acute childhood diarrhoea in Calcutta

Of the 152 cases of acute diarrhoea, 124 (81.5%) revealed potential pathogens. Altogether 27 (21.2%) out of 127 strains of Escherichia coli, Klebsiella pneumoniae, Enterobacter, Proteus and Acinetobacter produced enterotoxin. Single pathogenic bacteria (40 cases 26.3%), parasite (6; 6%), rota virus (6; 6%), toxigenic bacteria (19; 12.5%) and mixed agents (37; 24.24.3%) were recorded in 108 cases (71.0%). Another 14 (9.2%) cases exclusively revealed moderate to heavy growth of suspected enteric pathogens like K. pneumoniae, Proteus, Enterobacter, Pseudomonas aeruginosa, anaerogenic E. coli and Citrobacter and 2 (1.3%) had high counts of T'. hominis. Of the known pathogens, the preponderance of A. hydrophila (24.4%), rota virus (15.7%) and Aeromonas hydrophila (14.0%) in 1-4 y, Vibrio cholerae (45.6%) and Trichuris trichiura (13.0%) in 4-14 y age group is highlighted. Other pathogenic bacteria were non-01 V. cholerae (3.2%), V. parahaemolyticus (2.6%), V. fluvialis (0.6), Plesiomonas shigelloides (3.9%), Salmonella (2.6%), Shigella (1.9%), EPEC (1.9%), EEC (5.2%) and Campylobacter jejuni (3.9%) and the parasites were Entamoeba histolytica (2.6%) and Giardia intestinalis (2.6). Comparative study of age matched controls with those of diarrhoea suggested the pathogenic role of E. histolytica and T. hominis.     

Socioeconomic effects of acute diarrhoea in adults

Epidemiological features and socioeconomic importance of acute diarrhoea in adults were studied in a prospective investigation of 309 patients and 240 controls in the city of Malm?, Sweden. Data from a national survey of 6,000 individuals interviewed for gastrointestinal and other symptoms were included. The age group 20-35 years constituted half of the patients. Although 41% of all patients were travellers--and travelling is more common in young people--the age distribution was not due to travelling habits alone. A relative risk of attracting diarrhoea abroad in different geographical regions is indicated, tropical Africa and Romania having the highest risk factors. The community costs of diarrhoea depend much more on production loss by the affliction of young people than direct costs for medical care. Preventive measures would be economically rewarding.     

Aetiology of acute diarrhoea in adults.

We have studied 73 adults with acute diarrhoea and identified a micro-organism or toxin likely to be the cause in 58%. In addition to routinely cultured bacteria, Campylobacter coli/jejuni and Clostridium difficile were important pathogens in the community. Patients who developed diarrhoea after antibiotic use had a distinctive clinical syndrome and comprised the third largest group of cases. Clinical, epidemiological, and histological features in an additional group with negative cultures and no antibiotic history suggest that an additional bacterial pathogen remains to be identified as a cause of acute diarrhoea in adults.     

Cryptosporidium among children with acute diarrhoea in the west of Ireland

During a period of 12 months beginning on 18 February 1985, 1246 specimens of faeces from 935 children aged 3 weeks to 12 years with acute diarrhoea of varying severity were examined for the presence of cryptosporidium oocysts. Twenty-six patients required admission to hospital; four of them needed intravenous rehydration. Predominant clinical features were diarrhoea, often watery, and vomiting. Diarrhoea varied in duration between 7-15 days. Cryptosporidium oocysts were found in specimens from 41 patients, an incidence of 4.3%. In four patients an additional enteropathogen was identified (Campylobacter species in two and enteropathogenic Escherichia coli in two - serotypes 0126: K71 (B16) and 018C: K77 (B12]. None of the patients had recently travelled abroad. Of the children 23 were from a farming or rural background. Eight of the farms had recently had significant outbreaks of diarrhoea among calves. There was a marked seasonal variation with 27 of the cases arising between 18 February and 18 June, an incidence during this period of 8%.     

Management of protozoal diarrhoea in HIV disease

Summary Since the first reported case of HIV infection in 1981, many HIV-seropositive patients have died as a result of diarrhoea induced by opportunistic protozoal infections: pathogens that would normally cause only a transient illness in immunocompetent individuals. The introduction of highly active antiretroviral therapy (HAART) in 1996 has been associated with a significant decline in incidence and mortality arising from infections such as cryptosporidia and microsporidia. Previously, there were no chemotherapeutic agents known to be effective in eradicating these parasites, but since the availability of HAART, the memory of the emaciated terminally ill patient with advanced AIDS suffering from refractory diarrhoea will hopefully be a thing of the past. Significant advances in the knowledge of the pathogenesis of HIV disease, earlier detection and thus treatment of the virus, and availability of improved diagnostic techniques and HAART have transformed the way HIV-associated diarrhoea is managed. In this review, we look specifically at the management of protozoa-induced diarrhoea.     

Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia

Diarrhoea occurs frequently in neutropenic patients with acute leukaemia receiving chemotherapy and may be caused by either infection- or drug-induced cytotoxicity. Since Clostridium difficile is the most common cause of nosocomial infectious diarrhoea in non-haematologic patients, we were interested in its incidence in patients with acute myeloid leukaemia (AML). In this retrospective study, we analysed 134 patients with AML receiving a total of 301 chemotherapy courses. Diarrhoea occurred during 33% of all courses in 58 patients. C. difficile-associated diarrhoea (CDAD) occurred in 18% of all patients and 9% of all treatment courses. Almost one third of diarrhoea episodes were caused by C. difficile. CDAD was associated with older age (58 vs. 50 years), number of antibiotics administered (2 vs. 1), duration of antibiotic therapy (7 vs. 4 days), ceftazidime as the antibiotic of choice (75% vs. 54%) and duration of neutropenia (12 vs. 7 days) prior to onset of diarrhoea. An increased risk for CDAD was seen for prolonged neutropenia. CDAD responded well to oral metronidazole and/or vancomycin and no patient died of this complication. In conclusion, CDAD is common in patients with AML receiving chemotherapy. C. difficile enterotoxin testing of stool specimens should be included in all symptomatic patients.     

Aetiology of acute diarrhoea in hospitalized children in Hong Kong

To determine the role of enteric pathogens in acute childhood diarrhoea in Hong Kong, 388 children with diarrhoea and 306 children of similar age without diarrhoea were evaluated in a hospital-based study during a one-year period from August 1994 to July 1995. Of the diarrhoeal cases, 55% were under 1 year and 95% were below 5 years of age. On admission, 22% had some dehydration but none was severely dehydrated. All children were well nourished. Over 60% of children with diarrhoea had one or more pathogens in their stool. Rotavirus was the most commonly isolated pathogen (34.6%), followed by Salmonella (23.3%), Campylobacter (4.7%) and Shigella (2.1%). Rotavirus was not assessed in the controls and was detected mainly during the winter months December to February. Bacterial pathogens were identified more commonly in diarrhoea patients (30%) than in controls (5.6%) (P<0.001). Despite rapid recent socioeconomic development in Hong Kong, non-typhoidal Salmonella diarrhoea remains a significant local problem in infants under 1 year. Further detailed assessment of the transmission and prevention of this infection is required.